Specifications TableSubject area*Biology*More specific subject area*Molecular Genetics*Type of data*Tables*How data was acquired*Whole exome sequencing was performed as described in the related research article*[@bib1]*. Exons were captured from fragmented and adaptor ligated genomic DNA samples using the SureSelect Human All Exon v.5 containing* 51 Mb *(Agilent Technologies, Santa Clara, CA). Paired-end 2x101-base massively parallel sequencing was carried out on the Illumina HiSeq2500 platform (Illumina, San Diego, CA), according to the manufacture\'s protocols. Base calling was performed by the Illumina CASAVA software (version 1.8.2) with default parameters.*Data format*Analyzed*Experimental factors*Sequencing reads were aligned to the human reference genome (GRCh37-derived alignment set used in 1000 Genomes Project) and the Genome Analysis Toolkit (GATK, v.2.6--5) was used to generate variant calls as previously described*[@bib1]*.*Experimental features*Families delivering a baby with a congenital heart defect (CHD) requiring surgical repair in infancy were recruited for the study. Experimental methods were described in the related research article.*^*1*^*Briefly,*\
*(i) The placenta and neonate were weighed and measured.*\
*(ii) Exome sequencing was performed on the subjects (N* = *133) and their parents (N* = *114 parent-child trios and 15 parent-child duos).*\
*(iii) The GeneVetter analysis tool (default settings) was used to identify damaging coding sequence variants in genes identified as positive regulators of angiogenesis (PRA) (GO:0045766).*\
*(iv) The effect of inherited and not inherited parental damaging PRA variants on placental function and fetal growth were examined.*Data source location*[Data source:]{.ul} Division of Cardiothoracic Surgery, The Children\'s Hospital of Philadelphia, Philadelphia, PA*\
*[Data analysis:]{.ul} Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI*Data accessibility*All of the data is presented in this article. The subjects were not consented for the raw sequence data to be released to a public database so what is presented is the analyzed and summarized data.*Related research article*M.W. Russell, J.S. Moldenhauer, J. Rychik, N.B. Burnham, E. Zullo, S.I. Parry, R.A. Simmons, M.A. Elovitz, S.C. Nicolson, R.L. Linn, M.P. Johnson, S. Yu, M.G. Sampson, H. Hakonarson, J.W. Gaynor. Damaging variants in pro-angiogenic genes impair growth in fetuses with cardiac defects. J Pediatr. 2019 Jun 18;.*[https://doi.org/10.1016/j.jpeds.2019.05.013](10.1016/j.jpeds.2019.05.013){#intref0010}*. \[Epub ahead of print\] PubMed PMID: 31227283.***Value of the data**•The presented data will facilitate the evaluation of fetal and maternal genetic variation on placental function and fetal growth in pregnancies involving a fetus with a CHD.•The data will directly benefit investigators examining the relationship between fetal growth and development and clinical outcomes in infants with critical CHD.•In the accompanying tables, different ways of grouping the data are used to examine the effects of inherited and not inherited genetic variation on placental function and fetal growth. The value of the data will be in the stimulation of ideas and approaches to estimate these complex genetic relationships.•Of particular interest is the potential interaction effect of damaging PRA variants present in both the mother and fetus. The interaction effect will require a much larger cohort to adequately assess; the presentation of the aggregate data using several different approaches will allow merging of the data with that from ongoing and future efforts.

1. Data {#sec1}
=======

We performed exome sequencing on infants with critical congenital heart disease (N = 133) and their parents (N = 114 parent-child trios and 15 parent-child duos). Using the GeneVetter program, we identified 113 pathogenic variants in the 163 positive regulators of angiogenesis (PRA) genes ([Table 1](#tbl1){ref-type="table"}) in 73 subjects (see [Table 2](#tbl2){ref-type="table"} for specific variants identified in the probands). To estimate the effects of the parental damaging PRA variants on placental function and fetal growth, we grouped the data to examine the effects from different perspectives. First, we examined the effects from the fetal perspective to assess whether a variant inherited or not inherited from either parent had an effect on placental function and fetal growth ([Table 3](#tbl3){ref-type="table"}). To remove the effects of having variants in both parents, we next restricted analysis to those cases where only a single parent had identified pathogenic variants ([Table 4](#tbl4){ref-type="table"}). Lastly, to specifically assess the effects of maternal variants on placental function and fetal growth, we grouped all cases based on the presence or absence of maternal variants that were inherited or not inherited ([Table 5](#tbl5){ref-type="table"}). The presented data will allow the examination of the effects of parental origin of inherited and not inherited variants on placental function and fetal growth in pregnancies involving CHD. In addition, it is anticipated that the different approaches to grouping the cases for analysis will help in the design and analysis of future work examining parental genetic factors impacting the maternal-fetal environment and fetal growth.Table 1Positive Regulation of Angiogenesis (PRA) gene set (GO:0045766).Table 1Positive Regulation of Angiogenesis (PRA)ABL1CX3CR1HSPB1PTGS2ACVRL1CXCL8HSPB6PTK2BADAM12CXCR2HYAL1RAMP2ADMCYBBIL10RAPGEF3ADM2CYP1B1IL1ARHOBAGGF1CYSLTR2IL1BRHOJAGO2DDAH1ISL1RLN2AGTR1DLL1ITGA5RRASAKT3ECM1ITGB1RUNX1ANGPT2Emilin2ITGB2S100A1ANGPT4ENGITGB8SASH1ANGPTL3EPHA1JAK1SEMA5AANGPTL4ERAP1JCADSERPINE1ANXA1ETS1JUPSFRP2ANXA3F3KDRSIRT1APELAFGF1KLF4SIRT6APLNRFGF18LRG1SMAD1AQP1FGF2MAP3K3SMOC2BMPERFGFBP1MTDHSP1BRCA1FLT1MYDGFSPHK1BTG1FOXC2NFE2L2SRPX2C3GAB1NODALSTAT3C3AR1GATA2NOS3STIM1C5GATA4NR2E1TBXA2RC5AR1GATA6NRP1TEKC6GDF2PAK4TN-WCCBE1GHRLPDCD6TERTCCL11GHSRPDCL3TGFBR2CCL24GREM1PDPK1THBS1CCR3HDAC7PGFTLR3CD34HDAC9PIK3C2ATMIGD2CD40HGFPIK3R6TNFSF12CDH5HIF1APLCG1TWIST1CELA1HIPK1PLK2UTS2RCHI3L1HIPK2PPP1R16BVASH2CHRNA7HK2PRKCAVEGFACIB1HMGA2PRKCBVEGFBCMA1HMGB1PRKD1VEGFCCTSHHMOX1PRKD2VEGFDCX3CL1HPSEPTGISWNT5AXBP1ZC3H12AZNF304Table 2Sequence variants identified as damaging by GeneVetter analysis in the 163 positive regulator of angiogenesis (PRA) genes (GO:0045766) in the cohort.Table 2Subject idgenechr:pos:ref:altidaa changeC57ABL19:133738189:G:Ars150134901E216KC1ADAM1210:127738138:G:C.C573WC17ADAM1210:127737958:T:Crs77297117N597SC135ADAM1210:127737958:T:Crs77297117N597SC44ANGPT28:6371240:C:Grs149383060L386FC84ANGPT28:6371240:C:Grs149383060L386FC59ANXA34:79522685:C:Trs5949P251LC87AQP17:30961780:C:T.R222CC120AQP17:30961753:G:Ars200906195V213MC73BRCA117:41246709:G:Crs80357199A280GC121BRCA117:41243948:C:G.Q1200HC44BRCA117:41256200:C:A.S127IC95C319:6693489:T:A.Q1055LC47C319:6686180:C:Grs371629277W1255CC132C65:41203257:G:T.H26NC66C65:41150035:A:Grs76202909C134C65:41150035:A:Grs76202909C95CCBE118:57364474:G:Trs191999971T34NC26CCR33:46307313:A:Grs138346219I243VC131CCR33:46307313:A:Grs138346219I243VC132CCR33:46306845:C:Trs201795127R87XC46CCR33:46307064:G:Ars145141172V160MC5CD341:208084424:A:Grs370283469M1TC89CD341:208072436:G:Ars148688256T133IC135CD341:208072436:G:Ars148688256T133IC56CDH516:66420973:G:A.A158TC51CDH516:66436582:G:Ars139612718R622QC44CHI3L11:203152888:G:Ars199779694R116CC39CHI3L11:203154465:C:Trs146010120R35QC128CHI3L11:203154468:T:C.Y34CC112CHRNA715:32393507:A:T.D95VC15CHRNA715:32450712:A:Grs142728508Y262CC125CIB115:90774612:G:A.S108FC129CTSH15:79224791:C:T.G139SC28CYP1B12:38298338:C:T.E387KC48CYP1B12:38298028:T:A.Q490LC108CYP1B12:38298028:T:A.Q490LC1CYP1B12:38302045:G:Ars104894978R163CC90CYP1B12:38301574:C:Ars72549382V320LC70CYP1B12:38297867:A:Trs368552668X544KC70EMILIN218:2913203:A:T.E988VC89EMILIN218:2913098:T:A.L953QC65EPHA17:143092241:C:A.E706DC30EPHA17:143095083:T:G.R515SC13EPHA17:143095862:C:T.V390MC18ETS111:128354768:T:C.K271RC40FGF15:141993631:C:Trs17223632G21EC67FGF15:141993631:C:Trs17223632G21EC66FGF185:170883784:G:Ars371575721R200QC68FLT113:28919631:G:Ars200840674A769VC13FLT113:28885760:G:Ars140861115P1201LC81FLT113:28885760:G:Ars140861115P1201LC75FOXC216:86602433:T:Crs61753346C498RC56FOXC216:86602272:A:Grs147258453Q444RC37GAB14:144359333:T:Crs201252337Y259HC75GDF210:48414216:C:Trs142402214D218NC114GDF210:48414216:C:Trs142402214D218NC32GHRL3:10328465:A:Grs376322935L86PC120HDAC712:48183606:C:Trs200899015R711HC123HDAC97:18629974:C:G.L94VC89HGF7:81374380:A:Crs139457161S228AC133HIF1A14:62194346:A:Crs373399672D273AC21HIPK27:139285223:C:Trs56132157R792QC89HK22:75105946:C:T.A388VC129HK22:75113788:C:Trs146476722P736LC115HK22:75106029:G:A.V416IC134HPSE4:84243462:C:T.G95SC5HPSE4:84216649:G:Ars144185023Q494XC140HPSE4:84216649:G:Ars144185023Q494XC26HSPB17:75932109:G:Crs367662394R27PC103HYAL13:50338090:C:T.A378TC124HYAL13:50339969:T:C.N140SC37IL1A2:113541307:C:Grs150033245C14SC9ITGB221:46308800:C:Trs2230531E630KC139ITGB221:46308800:C:Trs2230531E630KC140ITGB221:46308800:C:Trs2230531E630KC73JUP17:39925401:C:Trs144171604R176QC12KLF49:110249816:G:Ars139237114H287YC137MAP3K317:61767648:G:A.R394HC120NFE2L22:178096406:G:Ars141363120L309FC44NOS37:150693897:G:Ars141456642E156KC137NOS37:150693897:G:Ars141456642E156KC132NOS37:150706545:C:Trs368180942P795LC16NOS37:150709452:C:T.R1000WC55NOS37:150707257:G:Ars201579252R856HC18NRP110:33515198:C:T.R334HC62PAK419:39668385:C:G.P519RC52PAK419:39666005:C:Trs377696830S429LC89PDPK116:2627442:C:G.F242LC109PIK3C2A11:17150917:C:Trs149664988D777NC115PIK3C2A11:17172056:A:Grs138300747F439SC32PIK3C2A11:17191207:T:Crs142132566K28EC94PIK3C2A11:17140241:G:A.L996FC60PIK3C2A11:17126742:T:C.N1219DC68PIK3C2A11:17150848:G:Ars201036447R800WC5PLCG120:39801462:A:Trs147844565D1075VC27PLK25:57755583:C:Ars372211010E68DC4PRKD114:30396699:A:G.L7PC96PTGIS20:48164484:G:Ars200631702R91CC40PTGS21:186648228:G:A.P92LC93RAPGEF312:48137442:G:Ars200527655R566WC112RAPGEF312:48131987:C:Trs200517997S857NC138RAPGEF312:48141598:T:Crs146484121Y457CC44RHOJ14:63749908:G:Ars150345688E158KC100RHOJ14:63747854:G:Trs372472368C73SASH16:148865872:G:Ars75149315R1089QC111SASH16:148865872:G:Ars75149315R1089QC133SASH16:148867217:C:Trs200999161R1139WC104SASH16:148869462:G:Ars143577116R1171QC115SERPINE17:100780350:C:T.R386WC43SP112:53776845:C:G.Q372EC100TEK9:27169568:C:T.S190LC108UTS2R17:80332489:G:Ars201963255D97N[^1]Table 3Effect of parental damaging PRA variants on placental function and fetal growth. The data is evaluated from the fetal perspective. For example, for the question, "Was there a variant in the father that was inherited by the infant?", the "No" answer will include cases in which the father had no variants and cases in which the father did have a variant but it wasn\'t inherited by the proband.Table 3Available NWeight z-scoreHeight z-scoreHead circumference z-scoreUA PI z-scoreWas there a variant in the father that was inherited by the infant?Yes41−0.11 ± 0.92−0.12 ± 1.3−0.51 ± 1.11.28 ± 1.3No720.01 ± 0.88−0.04 ± 1.4−0.13 ± 1.20.79 ± 1.4*P-value0.530.770.100.11*Was there a variant in the father that wasn\'t inherited by the infant?Yes460.05 ± 0.87−0.07 ± 1.2−0.12 ± 1.10.82 ± 1.3No64−0.10 ± 0.92−0.06 ± 1.4−0.40 ± 1.30.99 ± 1.4*P-value0.400.970.220.59*Was there a variant in the mother that was inherited by the infant?Yes40−0.34 ± 0.89−0.60 ± 1.3−0.67 ± 1.11.08 ± 1.3No880.01 ± 0.950.05 ± 1.5−0.12 ± 1.20.80 ± 1.4*P-value0.0530.020.010.34*Was there a variant in the mother that wasn\'t inherited by the infant?Yes470.04 ± 0.890.04 ± 1.5−0.26 ± 1.10.86 ± 1.4No81−0.18 ± 0.97−0.27 ± 1.4−0.31 ± 1.20.92 ± 1.3*P-value0.190.260.790.83*[^2][^3]Table 4Effect of parental origin of damaging PRA variants on placental function and fetal growth. The data only includes those cases in which inherited variants or not inherited variants originate from a single parent. For example, for the question, "Was there a variant in the father that was inherited by the infant?", the "Yes" answer includes only those cases in which one or more variants were inherited from the father and no variants were inherited from the mother. Similarly, for the question, "Was there a variant in the father that wasn\'t inherited by the infant?", only those cases in which no PRA variant was noted in the proband [and]{.ul} there were 1 or more variants in the father were included.Table 4Available NWeight z-scoreHeight z-scoreHead circumference z-scoreUA PI z-scoreWas there a variant in the father that was inherited by the infant?Yes250.01 ± 0.97−0.02 ± 1.4−0.26 ± 1.01.36 ± 0.71Was there a variant in the mother that was inherited by the infant?Yes24−0.37 ± 0.95−0.82 ± 1.4−0.51 ± 1.11.03 ± 0.44*P-value0.170.0540.410.43*Was there a variant in the father that wasn\'t inherited by the infant?Yes31−0.04 ± 0.85−0.22 ± 1.1−0.18 ± 1.10.58 ± 0.05Was there a variant in the mother that wasn\'t inherited by the infant?Yes32−0.04 ± 0.88−0.06 ± 1.7−0.39 ± 1.20.70 ± 0.18*P-value0.970.650.480.74*[^4][^5]Table 5Effect of maternal damaging PRA variants on placental function and fetal growth. The data specifically examines the effects of maternal PRA variants. All probands with maternal data are included in the analysis. Each subject was assigned to one of the six categories based on variant distribution.Table 5Available NWeight z-scoreHeight z-scoreHead circumference z-scoreUA PI z-scoreNo damaging variant in infantNo damaging variant in mother370.09 ± 0.990.21 ± 1.20.14 ± 1.30.65 ± 1.41 or more damaging variant in mother200.12 ± 0.650.27 ± 1.7−0.33 ± 1.00.44 ± 1.5*P-value0.900.910.170.64*1 damaging variant in infantNot inherited from mother25−0.26 ± 1.1−0.43 ± 1.8−0.29 ± 1.11.14 ± 0.97Inherited from mother18−0.14 ± 1.0−0.72 ± 1.5−0.49 ± 1.31.45 ± 1.0*P-value0.700.580.570.40*2 + damaging variants in infantNone inherited from mother6−0.05 ± 1.0−0.03 ± 1.2−0.46 ± 0.901.96 ± 2.0At least one inherited from mother22−0.42 ± 0.79−0.43 ± 1.1−0.79 ± 1.10.81 ± 1.4*P-value0.350.440.500.14*[^6][^7]

2. Experimental design, materials, and methods {#sec2}
==============================================

For a complete description of the experimental design and methods, please see the related research article [@bib1]. Briefly, whole exome sequencing was performed on 133 subjects and all consented parents (114 parent-child trios, 15 parent-child duos and 4 child only). Exons were captured from fragmented and adaptor ligated genomic DNA samples using the SureSelect Human All Exon v.5 containing 51 Mb (Agilent Technologies, Santa Clara, CA). Paired-end 2 × 101-base massively parallel sequencing was carried out on the Illumina HiSeq2500 platform (Illumina, San Diego, CA), according to the manufacture\'s protocols. Base calling was performed by the Illumina CASAVA software (version 1.8.2) with default parameters. Sequencing reads passing the quality filter were aligned to the human reference genome (GRCh37-derived alignment set used in 1000 Genomes Project) with Burrows-Wheeler Aligner (BWA, v.0.7.12) and Dragen (Illumina, San Diego, CA) [@bib2]. PCR duplicates were removed using Picard (v.1.97; Broad Institute, Boston, MA). The Genome Analysis Toolkit (GATK, v.2.6--5; Broad Institute, Boston, MA) was used to generate variant calls. The Gene Ontology (GO) database was used to identify the target gene set. The GO term "positive regulator of angiogenesis" (PRA) (GO:0045766) was selected to minimize potential opposing effects of damaging variants in positive and negative regulators. The PRA gene set contains 163 genes ([Table 1](#tbl1){ref-type="table"}). Damaging variants in the PRA gene set were identified using the GeneVetter program, a web-based analysis tool designed to improve the accuracy of pathogenicity prediction for single nucleotide variants identified by exome sequencing [@bib3]. To be adjudicated as damaging by using the program\'s default settings, a variant must meet all of the following criteria: (i) have a maximum allele frequency in the sample population of \<0.05, (ii) be adjudicated as "Damaging" by at least 2 of 3 of the following algorithms: PolyPhen2, SIFT, and MutationTaster, and (iii) have a maximum allele frequency across European-Americans and African-Americans of \<0.005.
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[^1]: Chr:pos:ref:alt: (Chromosome:position:reference nucleotide; "altered" or substituted nucleotide) refers to the location of the genetic alteration with the position referring to the GRCh37/hg19 Assembly.

[^2]: \* Data are presented as Mean ± Standard deviation.

[^3]: ^§^ P-value from two-sample t-test.

[^4]: \*Data are presented as Mean ± Standard deviation.

[^5]: ^§^ P-value from two-sample t-test.

[^6]: \* Data are presented as Mean ± Standard deviation.

[^7]: § P-value from two-sample t-test.
